Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug;24(4):555-60.
doi: 10.3346/jkms.2009.24.4.555. Epub 2009 Jul 29.

Influence of lactate dehydrogenase and cyclosporine A level on the incidence of acute graft-versus-host disease after allogeneic stem cell transplantation

Moo-Kon Song  1 , Joo-Seop Chung, Young-Mi Seol, Bo-Ran Kwon, Ho-Jin Shin, Young-Jin Choi, Goon-Jae Cho
Affiliations

Influence of lactate dehydrogenase and cyclosporine A level on the incidence of acute graft-versus-host disease after allogeneic stem cell transplantation

Moo-Kon Song et al. J Korean Med Sci. 2009 Aug.

Abstract

Previous reports have suggested that a high serum cyclosporine A (CsA) level could result in a lower incidence of acute-graft-versus-host disease (aGVHD). An elevated serum lactate dehydrogenase (LDH) level has been reported to be an adverse predictor of outcome in stem cell transplantation (SCT) for acute myeloid leukemia. In this study, we retrospectively analyzed the records of 24 patients who received allogeneic SCT from an HLA-matched sibling donor for acute and chronic myelogenous leukemia. Univariate analysis showed that two factors (the serum CsA level at the third week after SCT and the LDH level at the third week after SCT) were significantly associated with the incidence of aGVHD among several variables (age, sex, stem cell source, cell dose, C-reactive protein, absolute lymphocyte count, conditioning regimens, and time to engraftment). A higher serum level of CsA and lower serum LDH level at the third week after SCT were associated with a lower incidence of aGVHD (P=0.015, 0.030). In multivariate analysis, the serum CsA level (hazard ratio [HR], 0.12; 95% confidence interval [CI], 0.022-0.652, P=0.0014) and serum LDH level (HR, 6.59; 95% CI, 1.197-36.316, P=0.030) at the third week after SCT were found to be independent factors that were significantly associated with the development of aGVHD. We conclude that a high CsA level and low LDH level might predict a low cumulative incidence of aGVHD after allogeneic transplantation from a matched sibling donor.

Keywords: Cyclosporine; Graft vs Host Disease; Leukemia, Myeloid, Acute.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The cumulative incidence of aGVHD of the two serum CsA groups at the third week after transplantation. A higher CsA level was associated with a lower incidence of aGVHD above grade II (P=0.0004). aGVHD, acute graft-versus-host disease; HCsA, higher cyclosporine A; LCsA, lower cyclosporine A.
Fig. 2
Fig. 2
The cumulative incidence of aGVHD of the two serum LDH groups at the third week after transplantation. A lower LDH level was associated with a lower incidence of aGVHD above grade II (P=0.0026). aGVHD, acute graft-versus-host disease; HLDH, higher lactate dehydrogenase; LLDH, lower lactate dehydrogenase.
Fig. 3
Fig. 3
The cumulative incidence of aGVHD of four groups (HCsA+LLDH, HCsA+HLDH, LCsA+LLDH, and LCsA+HLDH group) at the third week after transplantation. The HCsA+LLDH group showed significantly better results than the other groups (P=0.0016). aGVHD, acute graft-versus-host disease; HCsA, higher cyclosporine A; LCsA, lower cyclosporine A; HLDH, higher lactate dehydrogenase; LCsA, lower cyclosporine A.
See this image and copyright information in PMC

References

    1. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–735. - PubMed
    1. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, Hill R, Longton G, Lum L, Martin P, McGuffin R, Sanders J, Singer J, Stewart P, Sullivan K, Witherspoon R, Thomas ED. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986;68:119–125. - PubMed
    1. Kanda Y, Hyo R, Yamashita T, Fujimaki K, Oshima K, Onoda M, Mori T, Sakura T, Tanaka M, Sakai M, Taguchi J, Kurakawa M, Maruta A, Okamoto S, Sakamaki H Kanto Study Group of Cell Therapy. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol. 2006;81:838–844. - PubMed
    1. Schots R, Kaufman L, Van Riet I, Lacor P, Trullemans F, De Waele M, Van Camp B. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant. 1998;22:79–85. - PubMed
    1. Lee KH, Choi SJ, Lee JH, Lee JS, Kim WK, Lee KB, Sohn SK, Kim JG, Kim DH, Seol M, Lee YS, Lee JH. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica. 2005;90:939–948. - PubMed

Publication types